Research Article| Volume 17, ISSUE 2, P315-319, March 1995

Comparison of the economic, clinical, and humanistic attributes of dihydroergotamine and sumatriptan

      This paper is only available as a PDF. To read, Please Download here.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Subcutaneous Sumatriptan International Study Group
        Treatment of migraine attacks with sumatriptan.
        NEJM. 1991; 325: 316-321
        • Cady RK
        • Wendt JK
        • Kirchner JR
        • et al.
        Treatment of acute migraine with subcutaneous sumatriptan.
        JAMA. 1991; 265: 2831-2835
        • Sumatriptan Auto-Injector Study Group
        Self-treatment of acute migraine with subcutaneous sumatriptan using an auto-injector device.
        Eur Neurol. 1991; 31: 323-331
        • Dahloff C
        • Edwards C
        • Toth AL
        Sumatriptan injection is superior to placebo in the acute treatment of migraine with regard to both efficacy and general well-being.
        Cephalalgia. 1992; 12: 214-220
        • Jhingran P
        • Grice RB
        • Miller DW
        • Gutterman DL
        Assessment of health-related quality of life, disability and productivity in migraine patients exposed and unexposed to sumatriptan.
        Presented at the Annual Meeting of the American Public Health Association. 3031994; (Washington, DC)
        • Scott AK
        Dihydroergotamine: A review of its use in the treatment of migraine and other headaches.
        Clin Neuropharmacol. 1992; 15: 289-296
      1. Imitrex® (sumatriptan succinate) Injection Product Information. Cerenex Pharmaceuticals, Division of Glaxo Inc, Research Triangle Park, NC, May 1994.

        • Winner P
        • Dalessio D
        • Matthew N
        • et al.
        Office-based treatment of acute migraine with dihydroergotamine mesylate.
        Headache. 1993; 33: 471-475
        • Saadah HA
        Abortive headache therapy with intramuscular dihydroergotamine.
        Headache. 1992; 32: 18-20
      2. D.H.E. 45® (dihydroergotamine mesylate) Injection Product Information. Sandoz Pharmaceuticals Corp, East Hanover, NJ, April 1993.

        • Modell B
        • Guiliano R
        A prospective evaluation of intramuscular dihydroergotamine for the control of acute migraine in the office setting.
        Clin Pharmacol Ther. 1993; 53 (Abstract): 225
        • Klapper JA
        • Stanton J
        Clinical experience with patient-administered subcutaneous dihydroergotamine mesylate in refractory headache.
        Headache. 1992; 32: 21-23
        • Osterhaus JR
        • Gutterman DL
        • Plachetka JR
        Health care resource and lost labour costs of migraine headache in the US.
        PharmacoEconomics. 1992; 2: 67-76
        • Jones A
        • Harrop C
        Study of migraine and the treatment of acute attacks in industry.
        J Int Med Res. 1980; 8: 321-325